Homocysteine levels in acromegaly patients

Simple item page
dc.contributor.authorHekimsoy Z.
dc.contributor.authorÖzmen B.
dc.contributor.authorUlusoy S.
dc.date.accessioned2024-07-22T08:24:10Z
dc.date.available2024-07-22T08:24:10Z
dc.date.issued2005
dc.description.abstractAcromegaly is associated with a two to three-fold increase in mortality related predominantly to cardiovascular disease. The excess mortality is associated most closely with higher levels of growth hormone (GH). Survival in acromegaly may be normalized to a control age-matched rate by controlling GH levels; in particular, GH levels less than 2.5 ng/mL are associated with survival rates equal to those of the general population. Hyperhomocysteinemia has also been recognized as a risk factor for cardiovascular disease, yet there are limited data on the prevalence of hyperhomocysteinemia in patients with acromegaly. Eightee n acromegaly patients (7 male, 11 female, mean age 42.8 ± 11.0 years) in our endocrine clinic consented to having the following tests performed: complete blood count (CBC), thyroid hormones, folic acid, vitamin B12, plasma homocysteine levels, uric acid, fibrinogen, CRP, fasting glucose, insulin, C-peptide, total serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, GH,insulin-like growth factor-1 (IGF-1) and GH levels after an oral glucose tolerance test (OGTT). By history, fourteen had macroadenomas and four had microadenomas; eight had hypertension; two had glucose intolerance, and four had diabetes. Fifteen had had transsphenoidal or transfrontal surgery: two had been cured, but 13 others were taking long-acting octreotide. Five patients had undergone radiotherapy and the acromegaly in two was treated primarily with long-acting octreotide. CBC, thyroid hormone, folic acid, and vit B12 levels were normal in all patients. We divided the patients into two groups according to mean GH levels after an OGTT: Group 1 (GH<2.5 ng/mL, n=10), and Group 2 (GH≥2.5 ng/mL, n=8). Comparison of the two groups using Mann-Whitney U testing revealed statistically significant lower levels in Group 1 of the following parameters: GH (1.91 ± 0.90 vs. 8.58 ± 5.55 ng/mL, p=0.002), IGF- 1 (338.30 ± 217.90 vs. 509.60 ± 293.58 ng /dL, p=0.06), GH after an OGTT (1.42 ± 0.81 vs. 9.01 ± 4.53 ng/mL, p=0.001), plasma homocysteine (12.85 ± 4.47 vs. 18.20 ± 4.99 μmol/L, p=0.05), total cholesterol (164.0 ± 20.81 vs. 188.0 ± 22.26 mg/dL, p=0.05) and LDL cholesterol (8 1.0 ± 9.64 vs. 116.70 ± 13.03 mg/dl, p=0.01). Differences between the other parameters were not significantly different. Acromegaly patients with high GH levels after an OGTT have much higher levels of homocysteine than patients with lower GH levels. The role of elevated homocysteine levels as an independent cardiovascular risk factor in the mortality of acromegaly patients should be determined in future studies. © Neuroendocrinology Letters.
dc.identifier.issn0172780X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19865
dc.language.isoEnglish
dc.publisherMaghira and Maas Publications
dc.subjectC peptide
dc.subjectC reactive protein
dc.subjectcholesterol
dc.subjectcyanocobalamin
dc.subjectfibrinogen
dc.subjectfolic acid
dc.subjectglucose
dc.subjectgrowth hormone
dc.subjecthigh density lipoprotein cholesterol
dc.subjecthomocysteine
dc.subjectinsulin
dc.subjectlong acting drug
dc.subjectlow density lipoprotein cholesterol
dc.subjectoctreotide
dc.subjectsomatomedin
dc.subjectthyroid hormone
dc.subjecttriacylglycerol
dc.subjecturic acid
dc.subjectacromegaly
dc.subjectadult
dc.subjectage
dc.subjectarticle
dc.subjectblood cell count
dc.subjectcardiovascular disease
dc.subjectcholesterol blood level
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdiabetes mellitus
dc.subjectfemale
dc.subjectglucose blood level
dc.subjectglucose intolerance
dc.subjecthormone blood level
dc.subjecthormone determination
dc.subjecthuman
dc.subjecthyperhomocysteinemia
dc.subjecthypertension
dc.subjectmale
dc.subjectmicroadenoma
dc.subjectmortality
dc.subjectoral glucose tolerance test
dc.subjectprevalence
dc.subjectprotein blood level
dc.subjectradiotherapy
dc.subjectrank sum test
dc.subjectrisk factor
dc.subjectstatistical significance
dc.subjectsurvival rate
dc.subjecttranssphenoidal surgery
dc.subjecttriacylglycerol blood level
dc.titleHomocysteine levels in acromegaly patients
dc.typeArticle

Files

Collections

Scopus Koleksiyonu